Information intended for healthcare professionals only.
This formulary decision guide was developed from content provided by Mead Johnson Nutrition in a format developed by Guidelines in Practice.
- CMA is the most common childhood food allergy affecting 1.9–4.9% of infants1,2
- Key clinical guidelines recommend extensively hydrolysed formula (eHF) as first-line management for formula-fed infants with mild-to-moderate CMA2–4
- Nutramigen with LGG® has demonstrated short-term (symptom relief),5 medium-term (accelerated return to milk*)6 and long‑term (reduced future allergic manifestations*)7 benefits.
Nutramigen™ 1, 2 & 3 with LGG®
- Nutramigen with LGG is an eHF with a probiotic (LGG) for dietary management of infants with CMA, providing age-adapted nutrition to support growth8 and an accelerated return to milk.*6
|Age||Nutramigen with LGG||Tins per month|
|See tin label for detailed feeding guidance; HCP to determine the formula intake based on the individual situation|
Preparation and storage
- Wash hands; clean feeding utensils in water (≥10 minutes rolling boil)
- Boil fresh water; as soon as possible cool to room temperature; do not use softened water9
- Feed immediately or cover and store in a refrigerator at 2–4°C for ≤24 hours
- Store tin in a cool, dry place; after opening, keep tightly covered and use within 1 month.
- Do not freeze prepared formula and do not use if unrefrigerated for >2 hours
- Use formula that has been in contact with baby’s mouth within 1 hour and do not refrigerate
- Do not heat prepared formula in a microwave.
- Trial formula for up to 4 weeks to allow symptom recovery and formula acceptance2
- To confirm diagnosis of non IgE mediated allergy, reintroduce milk and monitor whether symptoms return2
- Guidelines recommend eHF for formula-fed infants for up to 2 years or until allergy is outgrown1
- ~50% of CMA infants remain allergic at 1 year of age with most reaching oral tolerance by the age of 3 years10
- A ‘planned reintroduction’ by an HCP will determine whether tolerance to milk protein has been acquired.2
- CMA is an adverse immune reaction to cow’s milk protein presenting with immediate (IgE mediated) and delayed (non Ige mediated) symptoms4
- Prevalence in infants is 1.9–4.9%1,2
- Children with CMA have an increased risk of other allergic manifestations.7
- For formula-fed infants, expert guidelines recommend eHF for first-line management of mild–moderate CMA2,4
- eHF is effective for symptom resolution in ~90% of infants with CMA,1,11 while AAF should be reserved for severe cases (~10%).2
Evidence for use
- Short-term: effective symptom relief:
- average clinical efficacy† of 99%3
- Medium-term: faster oral tolerance acquisition:*
- >80% of infants return to milk after 12 months of use6
- >80% of infants return to milk after 12 months of use6
- Long-term: reduction in future allergic manifestations:
- occurrence of ≥1 other allergic manifestation (asthma, eczema, urticaria, rhinoconjunctivitis) reduced by ~50% as shown in Figure 1.7
- Nutramigen with LGG reduced infant healthcare costs over 12-month and 18-month periods compared with AAF or eHF (without LGG).12–14
- Not recommended for premature and immunocompromised infants unless directed and supervised by an HCP
- Babies fed eHF may produce frequent loose stools of a greenish colour (not unusual).
Order and contact information
|UK pharmacy PIP order code||Nutramigen with LGG (400 g)||Age||NHS price|
|019-8861||1 (previously Nutramigen LIPIL 1)||0–6 months||£11.21|
|298-7766||2 (previously Nutramigen LIPIL 2)||6–12 months||£11.21|
For queries or milk-free recipes, please call the Mead Johnson Careline 01895 230575 or visit www.nutramigen.co.uk
- Breastfeeding provides the best nutrition for babies
- This material is for HCPs only
AAF=amino acid-based formula; CMA=cow’s milk allergy; eHF=extensively hydrolysed formula; HCP=healthcare professional; LGG=Lactobacillus rhamnosus GG.
* vs Nutramigen without LGG; † Efficacy data calculated using data on allergic reactions after oral food challenge with an eHF, from Table 3 of Dupont et al. 2012. As judged by the Committee on Nutrition of the French Society of Paediatrics. Efficacy data was calculated based on studies with Nutramigen before the addition of LGG.
- Fiocchi A, Brozek J, Schunemann H et al. World Allergy Organization (WAO) diagnosis and rationale for action against cow’s milk allergy (DRACMA) guidelines. World Allergy Organ J 2010; 3 (4): 57–161.
- Venter C, Brown T, Meyer R et al. Better recognition, diagnosis and management of non‑IgE‑mediated cow’s milk allergy in infancy: iMAP—an international interpretation of the MAP (Milk Allergy in Primary Care) guideline. Clin Transl Allergy 2017; 7: 26.
- Dupont C, Chouraqui J, de Boissieu D et al. Dietary treatment of cows’ milk protein allergy in childhood: a commentary by the Committee on Nutrition of the French Society of Paediatrics. Br J Nutr 2012; 107 (3): 325–338.
- Luyt D, Ball H, Makwana M et al. BSACI guideline for the diagnosis and management of cow’s milk allergy. Clin Exp Allergy 2014; 44 (5): 642–672.
- Baldassarre M, LaForgia N, Fanelli M et al. Lactobacillus GG improves recovery in infants with blood in the stools and presumptive allergic colitis compared with extensively hydrolyzed formula alone. J Pediatr 2010; 156 (3): 397–401.
- Berni Canani R, Nocerino R, Terrin G et al. Effect of Lactobacillus GG on tolerance acquisition in infants with cow’s milk allergy: a randomized trial. J Allergy Clin Immunol 2012; 129 (2): 580–582.
- Berni Canani R, Di Costanzo R, Bedogni G et al. Extensively hydrolyzed casein formula containing Lactobacillus rhamnosus GG reduces the occurrence of other allergic manifestations in children with cow’s milk allergy: 3-year randomized controlled trial. J Allergy Clin Immunol 2017; 139 (6): 1906–1913.
- Scalabrin D, Johnston W, Hoffman D et al. Growth and tolerance of healthy term infants receiving hydrolyzed infant formulas supplemented with Lactobacillus rhamnosus GG: randomized, double-blind, controlled trial. Clin Pediatr (Phila) 2009; 48 (7): 734–744.
- BDA. Guidelines for the preparation and handling of expressed and donor breast milk and special feeds for infants and children in neonatal and paediatric health care settings. British Dietetic Association. 2016. Available at: www.bda.uk.com/regionsgroups/groups/paediatric/sfu_guidelines (accesssed November 2018)
- GIKids. Cow’s milk protein intolerance. Factsheet. 2013. Available at: www.gikids.org/content/103/en/cows-milk-protein-intolerance (accessed November 2018)
- Meyer R, Groetch M, Venter C. When should infants with cow’s milk protein allergy use an amino acid formula? A practical guide. J Allergy Clin Immunol Pract 2018; 6 (2): 383–399.
- Guest J, Panca M, Ovcinnikova O, Nocerino R. Relative cost-effectiveness of an extensively hydrolyzed casein formula containing the probiotic Lactobacillus rhamnosus GG in managing infants with cow’s milk allergy in Italy. Clinicoecon Outcomes Res 2015; 7: 325–336.
- Guest J, Weidlich D, Mascunan Diaz J et al. Relative cost-effectiveness of using an extensively hydrolyzed casein formula containing the probiotic Lactobacillus rhamnosus GG in managing infants with cow’s milk allergy in Spain. Clinicoecon Outcomes Res 2015; 7: 583–591.
- Ovcinnikova O, Panca M, Guest J. Cost-effectiveness of using an extensively hydrolyzed casein formula plus the probiotic Lactobacillus rhamnosus GG compared to an extensively hydrolyzed formula alone or an amino acid formula as first-line dietary management for cow’s milk allergy in the US. Clinicoecon Outcomes Res 2015; 7: 145–152.
Trademark of Mead Johnson & Company, LLC. ©2019 Mead Johnson & Company, LLC.
All rights reserved. LGG® is a registered trademark of Chr. Hansen A/S. Nutramigen with LGG® is a food for specialist medical purposes and must be used under medical supervision.
Date of preparation: March 2019
- PDF, Size 0.26 mb